Advertisement

Diabetes Mellitus

  • Don Riesenberg

Abstract

The care of elderly patients with diabetes mellitus requires as much art as science. Today, our understanding of this heterogeneous disease is increasing rapidly. Yet, in the elderly population, the boundary between normal and abnormal glucose tolerance remains unclear, and there exists no perfect therapeutic substitute for glucose homeostasis—the complex interaction between pancreas, liver, and skeletal muscle.1

Keywords

Impaired Glucose Tolerance Elderly Person Macular Edema Plasma Glucose Level Aldose Reductase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeFronzo RA. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667–687.PubMedGoogle Scholar
  2. 2.
    Harris MI, Hadden WC, Knowler WC, et al: International Criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 1985; 8: 562–567.PubMedCrossRefGoogle Scholar
  3. 3.
    Little RR, England JD, Wiedmeyer HM, et al: Relationship of glycosylated hemoglobin to oral glucose tolerance. Diabetes 1988; 37: 60–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Arnetz BB, Kallner A, Theorell T. The influence of aging on hemoglobin A’c (HbA’c). J Gerontol 1982; 37: 648650.Google Scholar
  5. 5.
    Kabadi UM. Glycosylation of proteins: lack of influence of aging. Diabetes Care 1988; 11: 429–432.PubMedCrossRefGoogle Scholar
  6. 6.
    Harris MI, Hadden WC, Knowler WC, et al: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 1987; 36: 523–534.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosen OM. After insulin binds. Science 1987; 237: 1452 1458.Google Scholar
  8. 8.
    Fink RI, Kolterman OG, Griffin J, et al. Mechanisms of insulin resistance in aging. J Clin Invest 1983; 71: 1523 1535.Google Scholar
  9. 9.
    Stern MP. Type II diabetes mellitus: interface between clinical and epidemiological investigation. Diabetes Care 1988; 11: 119–126.PubMedCrossRefGoogle Scholar
  10. 10.
    American Diabetes Association. Nutritional Recommendations and principles for individuals with diabetes mellitus: 1986 Diabetes Care 1987; 10: 126–132.Google Scholar
  11. 11.
    Hollenbeck CB, Coulston AM, Reaven GM. Comparison of plasma glucose and insulin responses to mixed meals of high-, intermediate-, and low-glycemic potential. Diabetes Care 1988; 11: 323–329.PubMedCrossRefGoogle Scholar
  12. 12.
    Bantle JP, Laine DC, Thomas WJ. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. JAMA 1986; 256: 3241–3246.PubMedCrossRefGoogle Scholar
  13. 13.
    Lipson LG. Diabetes in the elderly: diagnosis, pathogenesis, and therapy. Am J Med 1986; 80 (suppl 5A): 10–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–1753.PubMedCrossRefGoogle Scholar
  15. 15.
    Holman RR, Steemson J, Darling P, et al. No glycemic benefit from guar adminstration in NIDDM. Diabetes Care 1987; 10: 68–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Seals DR, Hagberg JM, Hurley BF, et al. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. JAMA 1984; 252: 645649.Google Scholar
  17. 17.
    Reaven GM, Reaven EP. Age, glucose intolerance, and non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1985; 33: 286–290.PubMedGoogle Scholar
  18. 18.
    Kovisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92: 59–61.Google Scholar
  19. 19.
    The DCCT Research Group. The diabetes control and complications trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530–545.CrossRefGoogle Scholar
  20. 20.
    Melander A. Clinical pharmacology of sulfonylureas. Metabolism 1987; 36 (suppl 1): 12–16.PubMedCrossRefGoogle Scholar
  21. 21.
    Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671–678.PubMedCrossRefGoogle Scholar
  22. 22.
    Yoo J, Peter S, Kleinfeld M. Transient hypoglycemic hemiparesis in an elderly patient. J Am Geriatr Soc 1986; 34: 479–481.PubMedGoogle Scholar
  23. 23.
    Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. Br J Med 1988; 296: 949–950.CrossRefGoogle Scholar
  24. 24.
    Lev JD, Zeidler A, Kumar D. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide. Diabetes Care 1987; 10: 679–682.PubMedCrossRefGoogle Scholar
  25. 25.
    Scarlett JA, Gray RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabets Care 1982; 5: 353–363.Google Scholar
  26. 26.
    Clements RS, Bell DSH, Benbarka A, et al. Rapid insulin initiation in non-insulin-dependent diabetes mellitus. Am J Med 1987; 82: 415–419.PubMedCrossRefGoogle Scholar
  27. 27.
    Nathan DM, Roussell A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 334–340.PubMedGoogle Scholar
  28. 28.
    Bolli GB, Gerich JE. The “dawn phenomenon”: a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 746–750.PubMedCrossRefGoogle Scholar
  29. 29.
    Cryer PE. Glucose counterregulation in man. Diabetes 1981; 30: 261–264.PubMedGoogle Scholar
  30. 30.
    Kyllastinen M, Groop L. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res 1985; 17: 100–104.PubMedGoogle Scholar
  31. 31.
    Puxty JAH, Hunter DH, Burr WA. accuracy of insulin injection in elderly patients. Br Med J 1983; 287: 1762.CrossRefGoogle Scholar
  32. 32.
    Alexander WD, Tattersall R. Plastic insulin syringes: reuse or waste L8m a year. Br Med J 1988; 296: 877–878.CrossRefGoogle Scholar
  33. 33.
    Gale EAM, Dornan TL, Tattersall RB. Severely uncontrolled diabetes in the over-fifties. Diabetologia 1981; 21: 25–28.PubMedCrossRefGoogle Scholar
  34. 34.
    Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35: 737–741.PubMedGoogle Scholar
  35. 35.
    Fisher JN, Kitabchi AE. A randomized study of phospate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983; 57: 177–180.PubMedCrossRefGoogle Scholar
  36. 36.
    Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med 1982; 142: 517520.Google Scholar
  37. 37.
    Pezzarossa A, Taddei F, Cimicchi MC, et al. Perioperative management of diabetic subjects: subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11: 52–58.PubMedCrossRefGoogle Scholar
  38. 38.
    Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315 1321.Google Scholar
  39. 39.
    Lopes-Virella MF, Klein RL, Lyons TJ, et al. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 1988; 37: 550–557.PubMedCrossRefGoogle Scholar
  40. 40.
    Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599–606.PubMedCrossRefGoogle Scholar
  41. 41.
    Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988; 319: 542–548.PubMedCrossRefGoogle Scholar
  42. 42.
    Nathan DM, Singer DE, Godine JE, et al. Non-insulindependent diabetes in older patients: complications and risk factors. Am J Med 1986; 81: 837–842.PubMedCrossRefGoogle Scholar
  43. 43.
    Nathan DM, Singer DE, Godine JE, et al. Retinopathy in older type II diabetics: association with glucose control. Diabetes 1986; 35: 797–801.PubMedCrossRefGoogle Scholar
  44. 44.
    Yanko L, Goldbourt U, Michaelson IC, et al. Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men. Br J Ophthalmol 1983; 67: 759–765.PubMedCrossRefGoogle Scholar
  45. 45.
    Early Treatment Diabetic Retinopathy Study Research Group: photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–1805.Google Scholar
  46. 46.
    Ballard DJ, Humphrey LL, Melton JL III, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes 1988; 37: 405–412.PubMedCrossRefGoogle Scholar
  47. 47.
    Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–360.PubMedCrossRefGoogle Scholar
  48. 48.
    Luetscher JA, Kraemer FB. Microalbuminuria and increased plasma prorenin: prevalence in diabetics followed up for four years. Arch Intern Med 1988; 148: 937–941.PubMedCrossRefGoogle Scholar
  49. 49.
    Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357.PubMedCrossRefGoogle Scholar
  50. 50.
    Working Group on Hypertension in Diabetes. Statement on hypertension in diabetes. Diabetes Care 1987; 10: 764–776.CrossRefGoogle Scholar
  51. 51.
    Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589–596.PubMedCrossRefGoogle Scholar
  52. 52.
    Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119–125.PubMedCrossRefGoogle Scholar
  53. 53.
    Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J 1982; 285: 916918.Google Scholar
  54. 54.
    Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med 1988; 318: 1306–1309.PubMedCrossRefGoogle Scholar
  55. 55.
    Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients: long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 1987; 83: 653–660.PubMedCrossRefGoogle Scholar
  56. 56.
    Perlmuter LC, Hakami MK, Hodgson-Harrington C, et al. Decreased cognitive function in aging non-insulindependent diabetic patients. Am J Med 1984; 77: 1043 1048.Google Scholar
  57. 57.
    Larson EB, Reifler BV, Sumi SM, et al. Diagnostic tests in the evaluation of dementia: a prospective study of 200 elderly outpatients. Ann Intern Med 1986; 146: 1917 1922.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Don Riesenberg

There are no affiliations available

Personalised recommendations